Products
Rimonabant was on the market in the form of film-coated tablets (Acomplia, Zimulti) starting in 2006. Because the drug can cause psychiatric disorders such as depression as a side effect, it was withdrawn from the market in 2008.
Structure and properties
Rimonabant (C22H21Cl3N4O, Mr = 463.8 g/mol) is a chlorinated piperidine and pyrazole carboxamide derivative.
Effects
Rimonabant (ATC A08AX01) has appetite suppressant properties. The effects are due to selective antagonism at the cannabinoid-1 receptor CB-1. The endocannabinoid system is a physiologic system of the central nervous system that promotes the intake of tasty, sweet, or fatty foods. Rimonabant has a long half-life of up to 16 days.
Indications
For the treatment of overweight and obesity.
Dosage
According to the professional information. The tablets are taken once a day before breakfast.
Contraindications
Rimonabant is contraindicated in case of hypersensitivity as well as existing major depressive disorder and/or antidepressant treatment. For complete precautions, see the drug label.
Interactions
Rimonabant is metabolized by CYP3A and via amidohydrolase pathways. Corresponding drug-drug interactions with CYP inhibitors and inducers are possible.
Adverse effects
The most common potential adverse effects include upper respiratory tract infections and nausea. Psychiatric disorders such as depressive disorders, mood changes, anxiety, irritability, nervousness, and sleep disturbances have been frequently reported.